Infant Formula Safety Modernization Act of 2026
Rep. DeLauro Introduces the Infant Formula Safety Modernization Act to Require Stricter Germ Testing
This bill is currently in the early stages of the legislative process and is being reviewed by the House Committee on Energy and Commerce. It was recently introduced and is actively moving forward as it waits for committee action. There are no upcoming votes scheduled at this time.
Legislative Progress
Key Points
Impact Analysis
Personal Impact
Smaller infant formula manufacturers would face new compliance costs from mandatory pathogen testing, record-keeping, and rapid notification requirements. While larger companies may absorb these costs easily, smaller and newer market entrants could find the regulatory burden significant. On the other hand, consistent standards across all producers, including imports, levels the playing field.
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
4 articles
Bill would hold infant formula manufacturers responsible for contaminated products
Rep. Rosa DeLauro introduced the Infant Formula Safety Modernization Act following a botulism outbreak. The bill requires companies to notify the FDA of positive pathogen tests within 24 hours and mandates expanded testing for dangerous germs like Clostridium botulinum in production facilities.
Formula safety bill would modernize oversight of the infant formula supply
The Infant Formula Safety Modernization Act aims to close gaps in federal oversight. It mandates standardized environmental monitoring inside factories to detect contamination before it reaches products and requires manufacturers to alert the government immediately if dangerous germs are found.
Congressional Bill Would Direct FDA to Enforce Stronger Infant Formula Safety Oversight
This legislative proposal would expand required pathogen testing to include a comprehensive list of microorganisms. It compels manufacturers to notify the FDA of any positive test result even if the formula has not left the facility, ensuring earlier intervention in potential safety crises.
Source Information
Document Type
Congressional Bill
Official Title
Infant Formula Safety Modernization Act of 2026
Data Sources
Sponsor
Cosponsors
(18)Analysis generated by AI. Always verify with official sources.